Lumbar Discopathy. Intervertebral disc disorders with myelopathy, thoracolumbar region
Conditions
Interventions
Intervention 1: The group receiving tranexamic acid: 15-30 minutes before surgical incision, 15mg/kg tranexamic acid, which has been diluted with normal saline to a volume of 20 cc, will be administer
CSL Behring, Pennsylvania) dissolved in 50 ml of distilled water was administered intravenously as described by the manufacturer they receive . Intervention 3: Control group: They receive an equal vol
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: No history of drug allergy No history of thromboembolism and coagulation disorders No history of liver or kidney failure No history of heart disease and hypertension ASA I , II Patient consent to participate in the study
Exclusion criteria
Exclusion criteria: use of anticoagulants History of blood disorders and coagulopathy History of liver disease History of chronic kidney disease and creatinine greater than 2mg / dl History of thromboembolic events at any time
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of intraoperative bleeding in groups receiving tranexamic acid ,fibrinogen and control group. Timepoint: End of surgery. Method of measurement: Bleeding volume during field operation, blood gases, suction.;Determining the duration of surgery in the groups receiving tranexamic acid ,fibrinogen and the control group. Timepoint: End of surgery. Method of measurement: hours / minutes.;Amount of blood and blood products injected. Timepoint: End of surgery. Method of measurement: The number of units to be injected. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determining the duration of surgery in the groups receiving tranexamic acid ,fibrinogen and the control group. Timepoint: End of surgery. Method of measurement: hours / minutes.;Determination of recovery time after reverse dose injection in groups receiving tranexamic acid ,fibrinogen and control group. Timepoint: End of surgery. Method of measurement: hours / minutes.;Determining the length of stay in the intensive care unit in the groups receiving tranexamic acid ,fibrinogen and the control group. Timepoint: End of surgery. Method of measurement: hours / minutes. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSogol Asgari
Shahid Beheshti University of Medical Sciences
Outcome results
None listed